Evidence map›Paper›PMID 25650438›Full record

ReviewStem cells translational medicine2015

Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards.

Anna French, Christopher Bravery, James Smith, Amit Chandra, Peter Archibald, Joseph D Gold, Natalie Artzi, Hae-Won Kim, Richard W Barker, Alexander Meissner and 16 more

Abstract readReview
In one paragraph

Review in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Strategies for Regenerating the Lacrimal Gland.Current ophthalmology reports · 2017
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Anna FrenchOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and anna.french@casmi.org.uk david.brindley@ndorms.ox.ac.uk esnyder@sanfordburnham.org.
Christopher BraveryConsulting on Advanced Biologicals Ltd., London, United Kingdom;
James SmithOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and.
Amit ChandraCentre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, United Kingdom;
Peter ArchibaldCentre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, United Kingdom;
Joseph D GoldStanford Cardiovascular Institute.
Natalie ArtziInstitute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA;
Hae-Won KimDepartment of Dental Biomaterials, School of Dentistry.
Richard W BarkerOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and.
Alexander MeissnerHarvard Stem Cell Institute, Cambridge, Massachusetts; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA;
Joseph C WuStanford Cardiovascular Institute, Department of Medicine, and Department of Radiology, Stanford University School of Medicine, Stanford, California, USA;
Jonathan C KnowlesDepartment of Nanobiomedical Science BK21 Plus NBM Global Research Center of Regenerative Medicine, and Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute.
David WilliamsCentre for Biological Engineering, Wolfson School of Mechanical and Manufacturing Engineering, Loughborough University, Loughborough, United Kingdom;
Guillermo García-CardeñaBroad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; Center for Excellence in Vascular Biology, Department of Pathology, and Program in Developmental and Regenerative Biology, Harvard Medical School, Boston, Massachusetts, USA;
Doug SippRIKEN Center for Developmental Biology, Kobe, Japan;
Steve OhBioprocessing Technology Institute, A*STAR Agency for Science, Technology and Research, Singapore;
Jeanne F LoringDepartment of Chemical Physiology and Center for Regenerative Medicine, Scripps Research Institute, La Jolla, California, USA;
Mahendra S RaoNIH Center for Regenerative Medicine, Bethesda, Maryland, USA;
Brock ReeveHarvard Stem Cell Institute, Cambridge, Massachusetts;
Ivan WallOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and Department of Nanobiomedical Science BK21 Plus NBM Global Research Center of Regenerative Medicine, and Department of Biochemical Engineering, and Biomaterials and Tissue Engineering Laboratory, Department of Nanobiomedical Science and WCU Research Center, Dankook University, Cheonan, Republic of Korea;
Andrew J CarrOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, and.
Kim BureTAP Biosystems, Royston, United Kingdom;
Glyn StaceyNational Institute for Biological Standards and Control, a Centre of the MHRA, South Mimms, United Kingdom;
Jeffrey M KarpHarvard Stem Cell Institute, Cambridge, Massachusetts; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA; Center for Regenerative Therapeutics and Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA;
Evan Y SnyderSanford-Burnham Medical Research Institute, La Jolla, California, USA; Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA; Sanford Consortium for Regenerative Medicine, La Jolla, California, USA; anna.french@casmi.org.uk david.brindley@ndorms.ox.ac.uk esnyder@sanfordburnham.org.
David A BrindleyOxford-UCL Centre for the Advancement of Sustainable Medical Innovation and Harvard Stem Cell Institute, Cambridge, Massachusetts; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, USA; Saïd Business School, University of Oxford, Oxford, United Kingdom; Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, United Kingdom; Stanford-UCSF FDA Center of Excellence in Regulatory Science and Innovation (CERSI), San Francisco, California, USA anna.french@casmi.org.uk david.brindley@ndorms.ox.ac.uk esnyder@sanfordburnham.org.

Funding

Medical Research Council MR/L01324X/1
6 · The paper itself

Abstract

There is a need for physical standards (reference materials) to ensure both reproducibility and consistency in the production of somatic cell types from human pluripotent stem cell (hPSC) sources. We have outlined the need for reference materials (RMs) in relation to the unique properties and concerns surrounding hPSC-derived products and suggest in-house approaches to RM generation relevant to basic research, drug screening, and therapeutic applications. hPSCs have an unparalleled potential as a source of somatic cells for drug screening, disease modeling, and therapeutic application. Undefined variation and product variability after differentiation to the lineage or cell type of interest impede efficient translation and can obscure the evaluation of clinical safety and efficacy. Moreover, in the absence of a consistent population, data generated from in vitro studies could be unreliable and irreproducible. Efforts to devise approaches and tools that facilitate improved consistency of hPSC-derived products, both as development tools and therapeutic products, will aid translation. Standards exist in both written and physical form; however, because many unknown factors persist in the field, premature written standards could inhibit rather than promote innovation and translation. We focused on the derivation of physical standard RMs. We outline the need for RMs and assess the approaches to in-house RM generation for hPSC-derived products, a critical tool for the analysis and control of product variation that can be applied by researchers and developers. We then explore potential routes for the generation of RMs, including both cellular and noncellular materials and novel methods that might provide valuable tools to measure and account for variation. Multiparametric techniques to identify "signatures" for therapeutically relevant cell types, such as neurons and cardiomyocytes that can be derived from hPSCs, would be of significant utility, although physical RMs will be required for clinical purposes.

Indexed as

Biomedical ResearchDrug Evaluation, PreclinicalPluripotent Stem CellsHumansReference Standards

Identifiers

PMID25650438
PMCPMC4339854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.